Literature DB >> 28540455

Yellow sac spider (Cheiracanthium punctorium) bites in Slovenia: case series and review.

Tanja Varl1, Damjan Grenc1, Rok Kostanjšek2, Miran Brvar3,4.   

Abstract

In Central Europe, reports of human envenomation by Cheiracanthium punctorium, commonly known as the yellow sac spider, are sporadic, despite the fact that this species is widespread in Europe. However, in recent years, C. punctorium has been repeatedly described globally in medical and toxicological literature. Its venom was found to possess insecticidal, haemolytic, cytotoxic, and membrane-damaging activities. Its bite is often very painful, frequently associated with local and transient cutaneous and neurotoxic effects, but sometimes also with systemic symptoms which require medical help. The main objective of this article is to introduce more details about C. punctorium, the clinical manifestations and circumstances of its bite, the characteristics of its venom and proposed clinical management. The authors provide case reports of patients bitten by C. punctorium during the 10-year observational period. All patients presented in this article showed generally mild clinical manifestations and recovered completely without sequelae. No further treatment in terms of hospital surveillance or specific clinical measures was necessary in any of the reported cases.

Entities:  

Keywords:  Cheiracanthium punctorium; Europe; Spider bite; Spider venoms; Yellow sac spider

Mesh:

Substances:

Year:  2017        PMID: 28540455     DOI: 10.1007/s00508-017-1217-8

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  9 in total

1.  Novel class of spider toxin: active principle from the yellow sac spider Cheiracanthium punctorium venom is a unique two-domain polypeptide.

Authors:  Alexander A Vassilevski; Irina M Fedorova; Ekaterina E Maleeva; Yuliya V Korolkova; Svetlana S Efimova; Olga V Samsonova; Ludmila V Schagina; Alexei V Feofanov; Lev G Magazanik; Eugene V Grishin
Journal:  J Biol Chem       Date:  2010-07-24       Impact factor: 5.157

2.  An extensive case of dermonecrotic arachnidism.

Authors:  Sherrie J Divito; Justin M Haught; Joseph C English; Laura K Ferris
Journal:  J Clin Aesthet Dermatol       Date:  2009-09

Review 3.  A two year study of verified spider bites in Switzerland and a review of the European spider bite literature.

Authors:  Wolfgang Nentwig; Markus Gnädinger; Joan Fuchs; Alessandro Ceschi
Journal:  Toxicon       Date:  2013-07-18       Impact factor: 3.033

4.  Araneae Sloveniae: a national spider species checklist.

Authors:  Rok Kostanjšek; Matjaž Kuntner
Journal:  Zookeys       Date:  2015-01-21       Impact factor: 1.546

5.  Swiss prospective study on spider bites.

Authors:  Markus Gnädinger; Wolfgang Nentwig; Joan Fuchs; Alessandro Ceschi
Journal:  Swiss Med Wkly       Date:  2013-09-04       Impact factor: 2.193

6.  Structure of the yellow sac spider Cheiracanthium punctorium genes provides clues to evolution of insecticidal two-domain knottin toxins.

Authors:  M Y Sachkova; A A Slavokhotova; E V Grishin; A A Vassilevski
Journal:  Insect Mol Biol       Date:  2014-04-10       Impact factor: 3.585

Review 7.  Verified bites by yellow sac spiders (genus Cheiracanthium) in the United States and Australia: where is the necrosis?

Authors:  Richard S Vetter; Geoffrey K Isbister; Sean P Bush; Lisa J Boutin
Journal:  Am J Trop Med Hyg       Date:  2006-06       Impact factor: 2.345

Review 8.  The global epidemiology, syndromic classification, management, and prevention of spider bites.

Authors:  James H Diaz
Journal:  Am J Trop Med Hyg       Date:  2004-08       Impact factor: 2.345

9.  Rapid genetic and ecological differentiation during the northern range expansion of the venomous yellow sac spider Cheiracanthium punctorium in Europe.

Authors:  Henrik Krehenwinkel; Dennis Rödder; Magdalena Năpăruş-Aljančič; Matjaž Kuntner
Journal:  Evol Appl       Date:  2016-08-17       Impact factor: 5.183

  9 in total
  1 in total

1.  Yellow sac spiders.

Authors:  Georg Röggla
Journal:  Wien Klin Wochenschr       Date:  2017-11-06       Impact factor: 1.704

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.